Boiron SA (FRA:BON)

Market Cap	447.95M +14.2%
Revenue (ttm)	501.11M +2.8%
Net Income	32.64M +188.0%
EPS	1.88 +188.0%
Shares Out	n/a
PE Ratio	13.72
Forward PE	n/a
Dividend	1.35 (5.27%)
Ex-Dividend Date	Jun 3, 2026

Volume	n/a
Open	25.40
Previous Close	25.60
Day's Range	25.40 - 26.20
52-Week Range	20.90 - 31.35
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 18, 2026

About Boiron

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices (in vitro diagnostics), dietary supplements, herbal remedies, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive l...

• Industry: Pharmaceutical Preparations
• Founded: 1932
• Employees: 2,499
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BON

Financial Performance

In 2025, Boiron's revenue was 501.11 million, an increase of 2.78% compared to the previous year's 487.56 million. Earnings were 32.64 million, an increase of 187.96%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error